Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ICML 2019 | MANTLE-FIRST results: outcomes in R/R younger MCL by therapy type

Umberto Vitolo • 20 Jun 2019
ICML 2019
B-Cell Lymphoma Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Bendamustine Ibrutinib Rituximab
MANTLE-FIRST

The results from the MANTLE-FIRST study are discussed here by Umberto Vitolo, MD, Città della Salute e della Scienza University Hospital, Turin, Italy, at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland. The outcomes of younger patients with relapsed/refractory mantle cell lymphoma (MCL) are explored.

More from Umberto Vitolo

Non-Hodgkin lymphoma highlights from EHA 2025: bispecifics and CAR T-cells 1:42
Non-Hodgkin lymphoma highlights from EHA 2025: bispecifics and CAR T-cells
Umberto Vitolo • 14 Jun 2025
Guidance on the use of epcoritamab for the treatment of follicular lymphoma 1:25
Guidance on the use of epcoritamab for the treatment of follicular lymphoma
Umberto Vitolo • 14 Jun 2025
The EPCORE NHL-2 trial: epcoritamab plus GemOx in transplant-ineligible R/R DLBCL 1:46
The EPCORE NHL-2 trial: epcoritamab plus GemOx in transplant-ineligible R/R DLBCL
Umberto Vitolo • 14 Jun 2025
Epcoritamab monotherapy for R/R follicular lymphoma: pooled analysis of 3-year follow-up data 2:08
Epcoritamab monotherapy for R/R follicular lymphoma: pooled analysis of 3-year follow-up data
Umberto Vitolo • 14 Jun 2025

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals